A clinical trial involving somatropin recombinant, marketed as Genotropin, was listed as completed on August 10, 2026. The study, registered as NCT07542886, was titled "A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults."
The trial was designated Phase 1 and enrolled healthy adult participants. Its stated purpose was to examine how different injector pen devices influence the delivery and uptake of somatropin into the bloodstream. According to the registry entry, the trial status is now recorded as completed.
No results, efficacy data, or safety findings were included in this update. The listing reflects only the change in trial status and does not indicate outcomes of the comparison between injector pens.
Somatropin recombinant remains classified as unapproved for research use in the context described here. Readers interested in background on this compound can consult the compound overview for additional context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07542886"]